|View printer-friendly version|
|May 17, 2017 9:00 a.m.|
|Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference|
New Data To Be Presented Show Reduction in ER Visits and Hospitalizations in Patients with Varying
Levels of Disease Severity Following Use of Two Asthma Therapies
Data to be presented include three abstracts on CINQAIR®
(reslizumab) Injection, an interleukin-5 antagonist monoclonal antibody
(IgG4 kappa) approved by the
One abstract, to be presented via oral presentation, is based on a post-hoc pooled analysis of two phase 3, 52-week placebo-controlled trials from the BREATH program looking at the efficacy of CINQAIR in two populations: (1) adult patients with severe asthma (GINA steps 4 and 5) and (2) adult patients with severe asthma and ≥2 exacerbations in the previous year to study start. Two additional abstracts, both accepted for poster presentation, will explore the efficacy of CINQAIR® in patients eligible for treatment with omalizumab and the time between first dose and reduction in blood eosinophil levels, respectively.
Three abstracts from the company’s
Teva will also present an abstract on ProAir® HFA (albuterol
sulfate) Inhalation Aerosol which examines the proportion of
Finally, Teva will present one abstract comparing in-clinic vs at-home handheld spirometry testing as observed in one of the clinical trials for the investigational beclomethasone dipropionate breath-actuated inhaler (BAI).
“We are pleased to present data from our respiratory portfolio at this
The following Teva-sponsored data will be presented at the
CINQAIR® (reslizumab) Injection
ProAir® HFA (albuterol sulfate) Inhalation Aerosol
Beclomethasone dipropionate Breath-Actuated Inhaler (BAI)
About CINQAIR® (reslizumab) Injection
CINQAIR® is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa). IL-5 is the most selective eosinophil-active cytokine and plays a major role in the maturation, activation and survival of eosinophils. In asthma patients, the eosinophilic phenotype is associated with compromised lung function, more frequent symptoms, and increased risk of exacerbations. CINQAIR® binds to human IL-5 and prevents it from binding to the IL-5 receptor, thereby reducing eosinophilic inflammation.
CINQAIR is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in people aged 18 years of age and older whose asthma is not controlled with the current asthma medicines. When added to other medicines for asthma, CINQAIR helps prevent severe asthma attacks (exacerbations) and can improve your breathing.
Important Safety Information
What is the most important information I should know about CINQAIR® (reslizumab) Injection?
About ProAir® HFA (albuterol sulfate) Inhalation Aerosol
ProAir® HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Important Safety Information
About Beclomethasone dipropionate Breath-Actuated Inhaler (BAI)
Beclomethasone dipropionate Breath-Actuated Inhaler (BAI) is a systemic
corticosteroid delivered via BAI aerosol. Teva has filed an New Drug
Application (NDA) with the
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and allergic rhinitis. The Teva Respiratory portfolio is centered on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. The company’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Teva respiratory products, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Pharmaceutical Industries Ltd.